- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01601873
Propaten Randomized Investigation on Cost-benefit and Efficacy (PRICE)
A Randomized Controlled Comparative Study on Efficacy and Cost-effectiveness of Heparin-bonded Versus Non-heparin-bonded Polytetrafluroethylene Hemodialysis Access Grafts.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Study Design: This is a prospective, multi-institution, parallel-group, single-blinded, randomized-controlled, two-arm, effectiveness study comparing heparin-bonded (Propaten®) versus non-heparin-bonded arteriovenous grafts.
Procedure: In patients without usable native vein, prosthetic arteriovenous grafts will be implanted for hemodialysis access. Patients will be randomized intraoperatively to either conventional (Gore® Stretch) or heparin-bonded grafts (Gore® Propaten).
Course of Study: The study will accrue patients over the course of 5 years.
Enrollment: Enrollment will consist of adult patients who require hemodialysis. If the patient cannot have a native vein arteriovenous fistula, the patient is a candidate for arteriovenous graft. Patients will be screened and consented preoperatively. If the intraoperative decision is made that the patient will require a graft, randomization will occur and the patient will be considered enrolled.
Recruitment: The target population comprises of all adult patients aged 18 years and above with end stage renal disease requiring arteriovenous access for hemodialysis. The target for enrollment will be 200 patients.
Risks: The standard or known adverse events associated with graft implantation include thrombosis, infection, pseudoaneurysm, hematoma, and venous stenosis. There are case reports of heparin sensitivity. The investigators do not expect any additional physical risks other than an unintentional disclosure of sensitive patient health information.
Data Safety Monitoring: As the Principal Investigator of this study, Dr. Charlton-Ouw from the Department of Cardiothoracic and Vascular Surgery at The University of Texas at Houston Medical School will conduct the data safety monitoring of this study. He will annually meet with all other co-investigators to review the patients enrolled in this study. As part of the data safety monitoring plan, all patients enrolled until that point in time would be unblinded in order to review the outcomes. Interim analyses will be conducted at the one-year follow up time.
IND#: The devices that will be used are already approved by the FDA and do not have IND#.
Proposed Funding Source: The study is internally funded.
Communication of Study Results: The communication of study results will occur only between authorized individuals who are listed to take part in the study through our department. The individuals who will take part in the study will acknowledge and adhere to the importance of patient safety and the protection of their private information. The results of this study will be analyzed and published after the approval of the principal investigator, co-investigators, and biostatistician in a peer-reviewed scientific journal and/or presented at an international/national scientific conference or meeting regardless of outcome.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72205
- University of Arkansas for Medical Sciences (UAMS) & Central Arkansas Veterans Healthcare System (CAVHS)
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70121
- John Ochsner Heart & Vascular Institute Ochsner Medical Center
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- University Hospitals Cleveland Medical Center
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Department of Cardiothoracic and Vascular Surgery and Memorial Hermann Heart and Vascular Institute - Texas Medical Center
-
Houston, Texas, Verenigde Staten, 77089
- Department of Cardiothoracic and Vascular Surgery; Memorial Hermann Hospital Southeast
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Aged ≥18 years of all ethnicities
- End-stage Renal Disease stage 4 (GFR 15-29 ml/min 1.73m2) or stage 5 (GFR <15ml/min 1.73m2) per National Kidney Foundation guidelines
- Currently undergoing hemodialysis with a failure of previous access
- Expected to undergo hemodialysis within 6 months of presentation
Exclusion Criteria:
- Unable/refuse to abide with follow-up
- Known hypercoagulability syndrome or a bleeding disorder
- On a previous anticoagulant treatment
- Intraoperative decision in favor of fistula instead of graft
- Pregnant or breast-feeding women
- A documented history of heparin induced thrombocytopenia or allergy
- Active infections
- Evidence or suspicion of central vein stenosis
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: PROPATEN
patients with heparin-bonded graft implantation
|
Heparin-bonded graft implantation for hemodialysis vascular access
Andere namen:
|
Actieve vergelijker: Standard Graft
patients undergoing ePTFE hemodialysis graft implantation
|
non-heparin bonded conventional hemodialysis vascular access graft
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Primary Graft Patency Rate
Tijdsspanne: 12 months
|
Primary graft patency refers to the successful use of a vascular access for hemodialysis without any surgical or endovascular intervention.
|
12 months
|
Primary-Assisted Graft Patency Rate
Tijdsspanne: 12 months
|
Primary-assisted graft patency is defined as a patent access with evidence of malfunction that requires an open surgical or endovascular intervention.
|
12 months
|
Secondary Graft Patency Rate
Tijdsspanne: 12 months
|
Secondary graft patency is defined as a functional access following intervention for thrombosis or after any interposition grafting for any reason including stenosis, aneurysm or pseudoaneurysm.
|
12 months
|
Primary Graft Patency Rate
Tijdsspanne: 24 months after graft placement
|
Primary graft patency refers to the successful use of a vascular access for hemodialysis without any surgical or endovascular intervention.
|
24 months after graft placement
|
Primary-Assisted Graft Patency Rate
Tijdsspanne: 24 months after graft placement
|
Primary-assisted graft patency is defined as a patent access with evidence of malfunction that requires an open surgical or endovascular intervention.
|
24 months after graft placement
|
Secondary Graft Patency Rate
Tijdsspanne: 24 months after graft placement
|
Secondary graft patency is defined as a functional access following intervention for thrombosis or after any interposition grafting for any reason including stenosis, aneurysm or pseudoaneurysm.
|
24 months after graft placement
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Participants With Complications or Morbidity Attributable to the Study
Tijdsspanne: at least 1 year but up to two years
|
Complication/morbidity associated with both types of interventions
|
at least 1 year but up to two years
|
Cost Estimation and Analysis
Tijdsspanne: During the study period based on an average participant follow-up of 2 years after graft placement
|
Will be based on the difference between total cost analysed on the basis of the specific graft price, cost of re-intervention procedures if any, treatment of complications, hospital stay, etc., and compared for each study arm.
|
During the study period based on an average participant follow-up of 2 years after graft placement
|
Quality of Life (QoL) Comparison
Tijdsspanne: Participants would be followed for a period of 2 years after graft placement
|
Comparative assessment of quality of life reported by the patients in two arms
|
Participants would be followed for a period of 2 years after graft placement
|
Number of Postoperative Re-interventions
Tijdsspanne: at least 1 year but up to two years
|
at least 1 year but up to two years
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Kristofer M Charlton-Ouw, MD, University of Texas Health Science Center, UT Medical School Department of Cardiothoracic and Vascular Surgery, Houston
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CTVS-KC01
- UTHSCMS-12/0095 (Andere identificatie: UTHSC IRB)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Nierziekte in het eindstadium
-
Bristol-Myers SquibbVoltooidTrombose | Nierfunctiestoornis | Factor XI | ESRD (End-Stage Renal Disease)Verenigde Staten